Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Pituitary ACTH Hypersecretion (Cushing Disease) Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Pituitary ACTH Hypersecretion (Cushing Disease) Overview | 9 | 1 |
| Pipeline Products for Pituitary ACTH Hypersecretion (Cushing Disease) Comparative Analysis | 10 | 1 |
| Pituitary ACTH Hypersecretion (Cushing Disease) Therapeutics under Development by Companies | 11 | 1 |
| Pituitary ACTH Hypersecretion (Cushing Disease) Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Pituitary ACTH Hypersecretion (Cushing Disease) Pipeline Products Glance | 13 | 3 |
| Late Stage Products | 13 | 1 |
| Clinical Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Pituitary ACTH Hypersecretion (Cushing Disease) Products under Development by Companies | 16 | 1 |
| Pituitary ACTH Hypersecretion (Cushing Disease) Products under Investigation by Universities/Institutes | 17 | 1 |
| Pituitary ACTH Hypersecretion (Cushing Disease) Companies Involved in Therapeutics Development | 18 | 11 |
| Alder Biopharmaceuticals Inc. | 18 | 1 |
| Corcept Therapeutics Incorporated | 19 | 1 |
| Cyclacel Pharmaceuticals, Inc. | 20 | 1 |
| ElexoPharm GmbH | 21 | 1 |
| Ionis Pharmaceuticals, Inc. | 22 | 1 |
| Ipsen S.A. | 23 | 1 |
| Millendo Therapeutics, Inc. | 24 | 1 |
| Orphagen Pharmaceuticals, Inc. | 25 | 1 |
| Pfizer Inc. | 26 | 1 |
| Strongbridge Biopharma plc | 27 | 1 |
| XOMA Corporation | 28 | 1 |
| Pituitary ACTH Hypersecretion (Cushing Disease) Therapeutics Assessment | 29 | 9 |
| Assessment by Monotherapy Products | 29 | 1 |
| Assessment by Target | 30 | 2 |
| Assessment by Mechanism of Action | 32 | 2 |
| Assessment by Route of Administration | 34 | 2 |
| Assessment by Molecule Type | 36 | 2 |
| Drug Profiles | 38 | 24 |
| ALD-1613 - Drug Profile | 38 | 1 |
| Product Description | 38 | 1 |
| Mechanism of Action | 38 | 1 |
| R&D Progress | 38 | 1 |
| ATR-101 - Drug Profile | 39 | 1 |
| Product Description | 39 | 1 |
| Mechanism of Action | 39 | 1 |
| R&D Progress | 39 | 1 |
| BIM-23B065 - Drug Profile | 40 | 1 |
| Product Description | 40 | 1 |
| Mechanism of Action | 40 | 1 |
| R&D Progress | 40 | 1 |
| COR-005 - Drug Profile | 41 | 1 |
| Product Description | 41 | 1 |
| Mechanism of Action | 41 | 1 |
| R&D Progress | 41 | 3 |
| IONIS-GCCRRx - Drug Profile | 44 | 1 |
| Product Description | 44 | 1 |
| Mechanism of Action | 44 | 1 |
| R&D Progress | 44 | 1 |
| levoketoconazole - Drug Profile | 45 | 1 |
| Product Description | 45 | 1 |
| Mechanism of Action | 45 | 1 |
| R&D Progress | 45 | 2 |
| mifepristone - Drug Profile | 47 | 1 |
| Product Description | 47 | 1 |
| Mechanism of Action | 47 | 1 |
| R&D Progress | 47 | 3 |
| Monoclonal Antibodies to Antagonize Adrenal Corticotropic Hormone Receptor for Cushing Disease - Drug Profile | 50 | 1 |
| Product Description | 50 | 1 |
| Mechanism of Action | 50 | 1 |
| R&D Progress | 50 | 1 |
| MPP-482 - Drug Profile | 51 | 1 |
| Product Description | 51 | 1 |
| Mechanism of Action | 51 | 1 |
| R&D Progress | 51 | 1 |
| osilodrostat phosphate - Drug Profile | 52 | 1 |
| Product Description | 52 | 1 |
| Mechanism of Action | 52 | 1 |
| R&D Progress | 52 | 2 |
| pasireotide ER - Drug Profile | 54 | 1 |
| Product Description | 54 | 1 |
| Mechanism of Action | 54 | 1 |
| R&D Progress | 54 | 2 |
| seliciclib - Drug Profile | 56 | 1 |
| Product Description | 56 | 1 |
| Mechanism of Action | 56 | 1 |
| R&D Progress | 56 | 2 |
| Small Molecule to Antagonize Melanocortin Receptor 2 for Cushing Disease and Congenital Adrenal Hyperplasia - Drug Profile | 58 | 1 |
| Product Description | 58 | 1 |
| Mechanism of Action | 58 | 1 |
| R&D Progress | 58 | 1 |
| Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing Disease - Drug Profile | 59 | 1 |
| Product Description | 59 | 1 |
| Mechanism of Action | 59 | 1 |
| R&D Progress | 59 | 1 |
| Small Molecules to Inhibit CYP11B1 for Cushing Disease and Subclinical Hypercortisolism - Drug Profile | 60 | 1 |
| Product Description | 60 | 1 |
| Mechanism of Action | 60 | 1 |
| R&D Progress | 60 | 1 |
| Small Molecules to Modulate Cryptochrome for Metabolic and CNS Disorders - Drug Profile | 61 | 1 |
| Product Description | 61 | 1 |
| Mechanism of Action | 61 | 1 |
| R&D Progress | 61 | 1 |
| Pituitary ACTH Hypersecretion (Cushing Disease) Recent Pipeline Updates | 62 | 11 |
| Pituitary ACTH Hypersecretion (Cushing Disease) - Dormant Projects | 73 | 1 |
| Pituitary ACTH Hypersecretion (Cushing Disease) Product Development Milestones | 74 | 4 |
| Featured News &Press Releases | 74 | 1 |
| Apr 03, 2016: Alder Presents Preclinical Data for ALD1613 at ENDO 2016 | 74 | 1 |
| Jul 02, 2015: First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing Disease, a Serious Endocrine Disorder | 74 | 1 |
| Jan 29, 2015: COR-003 Phase 3 Study Protocol to be Presented at ENDO 2015: The Endocrine Society s 97th Annual Meeting &Expo | 75 | 1 |
| Oct 03, 2014: Cortendo AB to Present at the 13th Annual BIO Investor Forum in San Francisco October 7, 2014 | 75 | 1 |
| Sep 30, 2014: Cortendo AB to Present at the Epic Biotech Conference in London on October 2, 2014 | 75 | 1 |
| Sep 29, 2014: Cortendo AB to Present at the 14th Annual BIOTECH in Europe Forum in Basel September 30, 2014 | 75 | 1 |
| Aug 12, 2014: First Patient Enrolled into NormoCort Phase 3 SONICS Trial Following a Successful EU Investigator Meeting | 76 | 1 |
| Jul 09, 2014: CORTENDO Reports Continued Progress On Phase 3 SONICS Trial | 76 | 1 |
| Jul 30, 2012: Cortendo's NormoCort Receives Orphan Drug Designation From EMA To Treat Cushing Syndrome | 77 | 1 |
| Mar 15, 2012: Cortendo Receives FDA Orphan Drug Designation For NormoCort In Cushing Syndrome | 77 | 1 |
| Appendix | 78 | 2 |
| Methodology | 78 | 1 |
| Coverage | 78 | 1 |
| Secondary Research | 78 | 1 |
| Primary Research | 78 | 1 |
| Expert Panel Validation | 78 | 1 |
| Contact Us | 78 | 1 |
| Disclaimer | 79 | 1 |